Page 9 - Science Summit News Today

Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.

Vitaly Margulis, MD, discusses significant factors and comorbidities that may affect treatment decisions for patients with renal cell carcinoma.

Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.

 VRC hosts Panel Discussion at the Science Summit at UNGA78 on Sept 25, 16:00 to 18:30 JST, to discuss UN SDGs and the Value Model KYOTO, Japan, Sep 25, 2023 - (JCN Newswire) - How can purpose, value, and impact measurement serve as a guide for

On 15 September 2023, as part of the Science Summit at the 78th United Nations General Assembly (UNGA78), COST co-organised a session with the U.S. National Science Foundation AccelNET Program, in New York City, to discuss global scientific networking collaboration. For the first time, this concrete initiative joins two funding schemes and their projects. International collaborative research 

Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.

Value Research Center (VRC) at SSUNGA78: How Purpose, Value, and Impact will Drive a Sustainable Post-SDG Future

Value Research Center (VRC) at SSUNGA78: 'How Purpose, Value, and Impact will Drive a Sustainable Post- SDG Future'

Francisco J. Esteva, MD, PhD, discusses the use of CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.